There are currently 121 ongoing clinical trials involving Pulmonary Fibrosis
Of the 121 trials,44 trials are in Phase II
Furthermore, 27 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Pulmonary Fibrosis, a respiratory condition. Asia-Pacific boasts of the highest number of ongoing clinical trials involving Pulmonary Fibrosis. North America, and Europe are among some of the other prominent regions involved in Pulmonary Fibrosis-related drug trials.
Boehringer Ingelheim International GmbH: The leading ongoing Pulmonary Fibrosis related clinical trials sponsor
Boehringer Ingelheim International GmbH, a pharmaceutical company headquarter at Germany, is the top sponsor for Pulmonary Fibrosis-related ongoing clinical trials.
Assistance Publique - Hopitaux de Paris, Pliant Therapeutics Inc, Blade Therapeutics Inc, and University of Alabama at Birmingham are a few other notable sponsors involving Pulmonary Fibrosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Pulmonary Fibrosis
Nintedanib (Ofev, Cyendiv, Sevcad), Pirfenidone (Esbriet, Pirespa), and Prednisone (Rayos, Lodotra, Nocasio) are among the key marketed drugs involving Pulmonary Fibrosis.
Nintedanib (Ofev, Cyendiv, Sevcad) is an indolinone-derivative, acts as an antineoplastic agent. Nintedanib functions via the following Mechanism of Action: Fibroblast Growth Factor Receptor 1 Inhibitor; Fibroblast Growth Factor Receptor 2 Inhibitor; Fibroblast Growth Factor Receptor 3 Inhibitor; Platelet Derived Growth Factor Receptor Alpha Inhibitor; Platelet Derived Growth Factor Receptor Beta Inhibitor; Proto Oncogene Tyrosine Protein Kinase Src Inhibitor; Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor; Tyrosine Protein Kinase Lck Inhibitor; Tyrosine Protein Kinase Lyn Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor.
Nintedanib is indicated for the treatment of Pulmonary Fibrosis, and several other indications including Systemic Sclerosis (Scleroderma), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Interstitial Lung Fibrosis. Nintedanib was first approved in 2014 and is formulated as soft gelatin capsules for oral route of administration. The drug is marketed globally including the US, the UK, and Japan by Boehringer Ingelheim group (Boehringer Ingelheim International GmbH, Boehringer Ingelheim Ltd UK, etc).
Pirfenidone (Esbriet, Pirespa) is an 9t, and antifibrotic agent. Pirfenidone acts by reducing the production of fibroblasts and pro-fibrogenic substances in the lungs of Pulmonary Fibrosis (IPF), thus slowing disease progression. The exact mechanism of action is unknown. Esbriet is indicated in adults for the treatment of mild to moderate Pulmonary Fibrosis (IPF). The drug is marketed globally including the United States, Australia, France, Germany, and Japan by F. Hoffmann-La Roche Ltd. Pirfenidone was first approved in 2008 and is formulated as hard gelatin capsules, tablets and film-coated tablets for oral route of administration.
United States of America
Ireland
United States of America
United States of America
Japan
United Kingdom
United States of America
United States of America
Australia
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer